Hikma Pharmaceuticals PLC
HIK
ISIN GB00B0LCW083 / Valor 2324471
Hikma Pharmaceuticals PLC
UMushroom community rating:
About company
Hikma Pharmaceuticals PLC is a leading pharmaceutical company in the MENA region, supplying branded generics and in-licensed patented products to retail and hospital customers. With a global presence, the company operates 29 manufacturing plants, eight R&D centers, and employs approximately 9,100 people worldwide. Hikma manufactures and supplies over 760 products essential for healthcare professionals in North America, MENA, and Europe, catering to the needs of hospitals, physicians, and pharmacists.
Summarized from source with an LLMView SourceSector: HealthcareLatest Results (14.08.2024):
Revenue Growth
Hikma Pharmaceuticals PLC reported a 10% increase in Group revenue for the first half of 2024, reaching $1,569 million compared to $1,427 million in the same period of 2023. This growth was driven by strong performances across all three of its business segments: Injectables, Branded, and Generics.
Operating Profit
The Group's operating profit saw a significant rise of 43% in H1 2024, amounting to $351 million, up from $245 million in H1 2023. This increase was attributed to the robust performance of the Branded business and the strategic focus on higher-margin products.
Core EBITDA
Hikma Pharmaceuticals PLC maintained a strong core EBITDA margin of 28.9% in H1 2024, although slightly down from 31.6% in H1 2023. The core EBITDA for the period was $453 million, reflecting the company's efficient cost management and operational effectiveness.
Interim Dividend
The company declared an interim dividend of 32 cents per share for H1 2024, representing a 28% increase from the 25 cents per share declared in H1 2023. This increase underscores Hikma's commitment to returning value to its shareholders.
Outlook for 2024
Hikma Pharmaceuticals PLC has upgraded its full-year 2024 guidance, now expecting Group revenue growth of 6% to 8%, up from the previous forecast of 4% to 6%. Additionally, the Group core operating profit is projected to be between $700 million and $730 million, reflecting the company's strong performance and positive market outlook.
Summarized from source with an LLMView SourceKey figures
Performance
Volatility
5232 M
Market cap (USD)
318,247
Daily traded volume (Shares)
18.72 / 18.21
1 day high/low (USD)
52 weeks high/low (USD)
Dividend ex-date
Dividend (USD)
Dividend yield (p.a.)
Est dividend (USD)
Est dividend yield
P/E ratio
Est P/E ratio
EPS (USD)
Est EPS (USD)
Ratings & reviews
EQUITIES OF THE SAME SECTOR
